Dyne Therapeutics, Inc. DYN Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $893.37M+105% | $435.45M+258% | $121.63M-29.3% | $172.15M-14.3% | ||
| $217.19M+5.0% | $206.82M+13,931% | $1.47M-98.2% | $83.87M-52.3% | ||
| $1.13B+70.9% | $659.28M+410% | $129.38M-51.3% | $265.59M-30.5% | ||
| $24.03M+345% | $5.4M+12.9% | $4.78M-19.6% | $5.95M+27.1% | ||
| $1.19B+71.7% | $691.23M+319% | $165.08M-46.1% | $306.33M-28.0% | ||
| $8.08M+23.2% | $6.56M-71.4% | $22.94M+336% | $5.26M+30.5% | ||
| $50.63M+19.8% | $42.26M-17.3% | $51.1M+81.9% | $28.09M-2.2% | ||
| $148.92M— | $0— | —— | —— | ||
| $214.83M+250% | $61.4M-16.8% | $73.79M+36.7% | $53.96M-6.1% | ||
| $16K+60.0% | $10K+66.7% | $6K0.0% | $6K0.0% | ||
| -$1.4B-47.0% | -$949.93M-50.2% | -$632.51M-59.5% | -$396.57M-73.6% | ||
| $972.13M+54.3% | $629.84M+590% | $91.29M-63.8% | $252.36M-31.5% | ||
| $1.19B+71.7% | $691.23M+319% | $165.08M-46.1% | $306.33M-28.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Dyne Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 19.92 — current assets exceed current liabilities.
- Where does Dyne Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.